JP2018502956A5 - - Google Patents

Download PDF

Info

Publication number
JP2018502956A5
JP2018502956A5 JP2017533008A JP2017533008A JP2018502956A5 JP 2018502956 A5 JP2018502956 A5 JP 2018502956A5 JP 2017533008 A JP2017533008 A JP 2017533008A JP 2017533008 A JP2017533008 A JP 2017533008A JP 2018502956 A5 JP2018502956 A5 JP 2018502956A5
Authority
JP
Japan
Prior art keywords
copolymer
repeating units
composition
nucleic acid
repeating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017533008A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018502956A (ja
JP6745272B2 (ja
Filing date
Publication date
Priority claimed from EP14199439.2A external-priority patent/EP3034539A1/en
Application filed filed Critical
Publication of JP2018502956A publication Critical patent/JP2018502956A/ja
Publication of JP2018502956A5 publication Critical patent/JP2018502956A5/ja
Application granted granted Critical
Publication of JP6745272B2 publication Critical patent/JP6745272B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017533008A 2014-12-19 2015-12-18 核酸を細胞内へ導入するための組成物 Active JP6745272B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14199439.2 2014-12-19
EP14199439.2A EP3034539A1 (en) 2014-12-19 2014-12-19 Compositions for introducing nucleic acid into cells
PCT/EP2015/080669 WO2016097377A1 (en) 2014-12-19 2015-12-18 Compositions for introducing nucleic acid into cells

Publications (3)

Publication Number Publication Date
JP2018502956A JP2018502956A (ja) 2018-02-01
JP2018502956A5 true JP2018502956A5 (enExample) 2019-02-07
JP6745272B2 JP6745272B2 (ja) 2020-08-26

Family

ID=52292658

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017533008A Active JP6745272B2 (ja) 2014-12-19 2015-12-18 核酸を細胞内へ導入するための組成物

Country Status (12)

Country Link
US (1) US11020487B2 (enExample)
EP (2) EP3034539A1 (enExample)
JP (1) JP6745272B2 (enExample)
KR (1) KR102142180B1 (enExample)
CN (1) CN107001627B (enExample)
AU (1) AU2015366220B2 (enExample)
BR (1) BR112017012482B1 (enExample)
CA (1) CA2971284C (enExample)
DK (1) DK3242903T3 (enExample)
ES (1) ES2887404T3 (enExample)
RU (1) RU2715227C2 (enExample)
WO (1) WO2016097377A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3034539A1 (en) 2014-12-19 2016-06-22 Ethris GmbH Compositions for introducing nucleic acid into cells
WO2017001570A2 (en) 2015-06-30 2017-01-05 Ethris Gmbh Atp-binding cassette family coding polyribonucleotides and formulations thereof
WO2018010815A1 (en) * 2016-07-15 2018-01-18 Biontech Rna Pharmaceuticals Gmbh Formulation for administration of rna
MX2020007477A (es) * 2018-01-11 2020-11-12 BioNTech SE Formulacion para la administracion de arn.
BR112020021054A2 (pt) 2018-04-25 2021-02-17 Ethris Gmbh composição, processo para a preparação de uma composição, e, composições sólida e para uso
IL293911A (en) * 2019-12-17 2022-08-01 Univ Gent Non-viral vectors consisting of polypropylene
CN111249476B (zh) * 2020-02-19 2023-09-26 深圳厚存纳米药业有限公司 泊洛沙姆和/或泊洛沙胺与脂质组合中性复合物纳米粒
US20240156729A1 (en) 2021-02-26 2024-05-16 Ethris Gmbh Formulations for aerosol formation and aerosols for the delivery of nucleic acid
EP4404973A4 (en) * 2021-09-22 2025-10-15 Sirnaomics Inc IMPROVED NANOPARTICLE FORMULATIONS FORMED FROM HISTIDINE-LYSINE COPOLYMERS
EP4404979A4 (en) * 2021-09-22 2025-10-08 Sirnaomics Inc PHARMACEUTICAL COMPOSITIONS OF NANOPARTICLES WITH REDUCED NANOPARTICLE SIZE AND IMPROVED POLYDISPERSITY INDEX
CN116549626A (zh) * 2022-01-27 2023-08-08 深圳瑞吉生物科技有限公司 一种载核酸脂质纳米颗粒冻干制剂及其制备方法与应用
CN120129532A (zh) 2022-08-26 2025-06-10 埃泽瑞斯公司 稳定的脂质或类脂质纳米颗粒悬浮液
EP4327829A1 (en) 2022-08-26 2024-02-28 Ethris GmbH Stabilization of lipid or lipidoid nanoparticle suspensions
WO2024240962A1 (en) 2023-05-25 2024-11-28 Ethris Gmbh Gm-csf-encoding nucleic acids, pharmaceutical compositions, methods and uses thereof
CN116478410B (zh) * 2023-06-20 2023-09-12 觅投克(北京)生物医学技术有限公司 一种菊糖修饰的聚乙烯亚胺衍生物及其制备方法和应用
CN121729225A (zh) 2023-08-25 2026-03-24 埃泽瑞斯公司 具有增强药物应用的特定表面活性剂性质的稳定脂质和类脂质纳米颗粒制剂
WO2025064850A1 (en) 2023-09-22 2025-03-27 BioNTech SE Rna constructs with n-terminal degrons to enhance an immune response
TW202539697A (zh) 2023-11-15 2025-10-16 德商拜恩技術股份公司 冠狀病毒疫苗
WO2025106738A1 (en) 2023-11-15 2025-05-22 BioNTech SE Sars-cov-2 immunogenic compositions
WO2026047603A1 (en) 2024-08-28 2026-03-05 BioNTech SE Sars-cov-2 immunogenic compositions
WO2026057626A1 (en) 2024-09-11 2026-03-19 BioNTech SE Peptidoglycan hydrolases having multiple enzymatically active domains
WO2026057625A1 (en) 2024-09-11 2026-03-19 BioNTech SE Peptidoglycan hydrolases having a chap domain with engineered active site
WO2026082899A2 (en) 2024-10-16 2026-04-23 BioNTech SE Rna for preventing or treating tuberculosis

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4711955A (en) 1981-04-17 1987-12-08 Yale University Modified nucleotides and methods of preparing and using same
JPS5821590A (ja) 1981-07-31 1983-02-08 株式会社東芝 制御棒駆動水圧装置
JPS58215490A (ja) * 1982-06-08 1983-12-14 Nippon Shokubai Kagaku Kogyo Co Ltd 石炭−水スラリ−用分散剤
CA1223831A (en) 1982-06-23 1987-07-07 Dean Engelhardt Modified nucleotides, methods of preparing and utilizing and compositions containing the same
US5792608A (en) 1991-12-12 1998-08-11 Gilead Sciences, Inc. Nuclease stable and binding competent oligomers and methods for their use
US5525711A (en) 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
FR2722506B1 (fr) 1994-07-13 1996-08-14 Rhone Poulenc Rorer Sa Composition contenant des acides nucleiques, preparation et utilisations
US5656611A (en) * 1994-11-18 1997-08-12 Supratek Pharma Inc. Polynucleotide compositions
DE19527102A1 (de) * 1995-07-25 1997-01-30 Bayer Ag Neue Polyamine und ihre Verwendung in Lacken und Beschichtungen
US6017700A (en) 1995-08-04 2000-01-25 Bayer Corporation Cationic oligonucleotides, and related methods of synthesis and use
FR2739292B1 (fr) 1995-09-28 1997-10-31 Rhone Poulenc Rorer Sa Composition pharmaceutique utile pour la transfection d'acides nucleiques et ses utilisations
EP1003527A4 (en) * 1997-08-01 2003-07-16 Supratek Pharma Inc POLYNUCLEOTIDE COMPOSITIONS
DE50006269D1 (de) 1999-06-25 2004-06-03 Stemberger Axel Kombinationen zur einführung von nucleinsäuren in zellen
DE19933024C2 (de) 1999-07-15 2003-03-13 Medinnova Ges Med Innovationen Kationische Blockcopolymere
WO2002000870A2 (en) 2000-06-26 2002-01-03 Christian Plank Method for transfecting cells using a magnetic field
US20030215395A1 (en) * 2002-05-14 2003-11-20 Lei Yu Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier
US20070269891A9 (en) * 2003-01-13 2007-11-22 Yasunobu Tanaka Solid surface with immobilized degradable cationic polymer for transfecting eukaryotic cells
JP4535229B2 (ja) 2003-05-08 2010-09-01 国立大学法人 東京大学 ポリエチレングリコール−ポリカチオンブロック共重合体
EP1859812B1 (en) 2005-02-10 2014-01-01 The University of Tokyo Polycation chargeable polymer and use as carrier of nucleic acid
EP2476756A1 (en) 2005-06-15 2012-07-18 Massachusetts Institute of Technology Amine-containing lipids and uses thereof
HUE043492T2 (hu) 2005-08-23 2019-08-28 Univ Pennsylvania Módosított nukleozidokat tartalmazó RNS és eljárások az alkalmazására
CA2633065C (en) 2005-12-15 2016-10-18 Centre National De La Recherche Scientifique (Cnrs) Cationic oligonucleotides, automated methods for preparing same and their uses
US7700541B2 (en) 2006-04-06 2010-04-20 Nitto Denko Corporation Biodegradable cationic polymers
GB0613753D0 (en) * 2006-07-11 2006-08-23 Norwegian Radium Hospital Res Method
BRPI0715375A2 (pt) * 2006-08-18 2013-06-18 Hoffmann La Roche policonjugados para distribuiÇço in vivo de polinucleotÍdeos
US20090042825A1 (en) * 2007-08-06 2009-02-12 Majed Matar Composition, method of preparation & application of concentrated formulations of condensed nucleic acids with a cationic lipopolymer
AU2009223313A1 (en) * 2008-03-14 2009-09-17 Egen, Inc. Biodegradable cross-linked branched poly (alkylene imines)
MX2011004859A (es) 2008-11-07 2011-08-03 Massachusetts Inst Technology Lipidoides de aminoalcohol y usos de los mismos.
WO2010065660A2 (en) 2008-12-02 2010-06-10 University Of Utah Research Foundation Biodegradable polydisulfide amines for gene delivery
EP3165234B1 (de) 2009-07-31 2019-04-03 ethris GmbH Rna mit einer kombination aus unmodifizierten und modifizierten nucleotiden zur proteinexpression
WO2011154331A1 (en) 2010-06-10 2011-12-15 F. Hoffmann-La Roche Ag Polymers for delivery of nucleic acids
EP2763701B1 (en) 2011-10-03 2018-12-19 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US9931418B2 (en) 2012-08-07 2018-04-03 Northeastern University Compositions for the delivery of RNA and drugs into cells
US10258698B2 (en) 2013-03-14 2019-04-16 Modernatx, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
EP3034539A1 (en) 2014-12-19 2016-06-22 Ethris GmbH Compositions for introducing nucleic acid into cells

Similar Documents

Publication Publication Date Title
RU2017122022A (ru) Композиция для введения нуклеиновой кислоты в клетки
JP2018519835A5 (enExample)
HRP20200407T1 (hr) Terapeutske polimerne nanočestice i postupci dobivanja i korištenja istih
Guzman-Villanueva et al. Formulation approaches to short interfering RNA and MicroRNA: challenges and implications
MX2013009191A (es) Oligonucleotidos antisentido.
JP2016517279A5 (enExample)
JP2023123491A5 (enExample)
JP2019515908A5 (enExample)
JP2019511491A5 (enExample)
JP2019516680A5 (enExample)
PH12015501445A1 (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
JP2011522070A5 (enExample)
CY1118700T1 (el) Συνδυασμοι φαρμακων για τη θεραπευτικη αντιμετωπιση της μυϊκης δυστροφιας duchenne
JP2016517888A5 (enExample)
JP2017141277A5 (enExample)
RU2015100198A (ru) Хиральный адъювант нуклеиновой кислоты
WO2016115543A3 (en) Novel micro-dystrophins and related methods of use
RU2017121299A (ru) ОПОСРЕДУЕМОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНОВ ВИРУСА ГЕПАТИТА B (HBV) С ПРИМЕНЕНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК)
WO2015106128A3 (en) Rnai agents modified at the 4'-c-position
EA201070421A1 (ru) Микрорибонуклеиновые кислоты
JP2015511821A5 (enExample)
JP2018530530A5 (enExample)
EP4410976A3 (en) Methods of using zscan4 for rejuvenating human cells
JP2015509705A5 (enExample)
JP2012505657A5 (enExample)